Ketamine's Regulatory Reckoning: From Rapid Growth to Enforcement

Ketamine clinics face rising U.S. regulatory scrutiny as rapid off-label growth outpaces clear federal standards for psychiatric use. The article links industry expansion to enforcement: oversight increasingly happens through audits, investigations, and actions by federal regulators and state medical boards rather than prospective guidance. It contrasts two delivery models, telemedicine and at-home compounded ketamine versus in-clinic IV infusion programs, and explains why telemedicine can raise higher risk after dispensing because providers lose control of storage and administration. For investigators and boards, the focus is operational and documentation based, including individualized treatment rationale, screening for contraindications and substance use risk, quality of physician supervision, and consistency between internal communications and patient records. DEA oversight emphasizes registration, inventory control, and record-keeping. The piece also highlights criminal enforcement where intent or departure from professional practice is evidenced by protocols, marketing, and communications, and notes a key deadline: COVID-era telemedicine flexibilities for controlled substance prescribing expire on December 31, 2025.